Navidea Biopharmaceuticals to Present at the Biotech Showcase Conference

– CEO to Provide Business & Development Program Updates –

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals (NYSE Amex: NAVB) today announced that Dr. Mark Pykett, President and CEO will participate at the Biotech Showcase Conference. Dr. Pykett will provide an update of the Company and its development programs on January 9, 2012 at 1:30 PM EST (10:30 AM PST) in San Francisco, CA.

Investors and the public are invited to listen to a live webcast of Dr. Pykett’s presentation at http://www.media-server.com/m/p/ern2i7ej. Following the conference, the webcast will be archived for approximately 30 days.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals (NYSE Amex: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScanTM – to help identify the presence and status of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

About the Biotech Showcase™ (Innovation – Opportunity – Collaboration):

Now in its fourth year, Biotech Showcase™ will feature corporate presentations by 200+ innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. The showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. To maximize efficiency, all showcase participants can schedule one-on-one meetings through the organizer’s online system, partneringONE®. Public and private investors are always invited to attend the showcase on a complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life sciences industry. Visit our website for more information: www.ebdgroup.com/bts.



CONTACT:

Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Sr. VP & CFO

KEYWORDS:   United States  North America  California  Ohio

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Medical Devices  Oncology  Pharmaceutical  FDA

MEDIA:

Logo
 Logo

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.